What is cardiac safety testing with organ-on-chip technology?

Cardiac safety testing uses heart-on-chip devices with human cardiomyocytes to assess whether drug candidates cause dangerous heart rhythm changes, structural damage, or reduced contractile function before clinical trials.

Why is cardiac toxicity a major concern in drug development?

Cardiac toxicity is the leading cause of drug withdrawals from the market and clinical trial failures. Traditional animal models poorly predict human cardiac responses, while human heart-on-chip models provide more accurate safety data.

What cardiac parameters can organ-on-chip models measure?

Heart-on-chip models can measure beat rate, contractile force, calcium transients, action potential duration, QT interval prolongation, and structural changes in real-time, providing comprehensive cardiac safety profiles for drug candidates.

Cardiac Safety Testing: Heart Organoids & Cardiotoxicity

45%
Drug Withdrawals
Due to cardiac effects

CiPA

Initiative

FDA/HESI program

iPSC-CM

Gold Standard

Human cardiomyocytes

MEA

Readout

Electrophysiology

THE CARDIAC SAFETY CHALLENGE

Cardiovascular toxicity accounts for approximately 45% of post-market drug withdrawals. Traditional hERG channel assays miss many cardiotoxic compounds. Human iPSC-derived cardiomyocytes and cardiac organoids now enable comprehensive assessment of drug effects on human heart tissue including contractility, electrophysiology, and structural toxicity.

KEY TECHNOLOGIES

iPSC-CARDIOMYOCYTES

Human Heart Cells

iPSC-derived cardiomyocytes provide human-relevant models for drug screening. They express cardiac ion channels and demonstrate beating, enabling assessment of pro-arrhythmic risk and contractile effects.

CARDIAC ORGANOIDS

3D Heart Models

Self-organizing cardiac organoids recapitulate heart chamber formation and contain multiple cardiac cell types. They enable study of structural cardiotoxicity and developmental effects.

HEART-ON-CHIP

Microfluidic Platforms

Heart-chips incorporate mechanical stretching to simulate cardiac workload. Valo Health acquired TARA Biosystems to integrate their beating heart-chip technology into drug discovery.

CiPA PARADIGM

Regulatory Framework

The Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative provides a regulatory-accepted framework for using human iPSC-cardiomyocytes in cardiac safety assessment.

KEY PROVIDERS

Platform

Valo Health

TARA heart-chip acquisition

iPSC-CM

FUJIFILM CDI

iCell Cardiomyocytes

Digital Twin

Dassault

Living Heart Project

❤️ Why Cardiac Safety Testing Matters

Cardiovascular toxicity is the leading cause of drug failures and market withdrawals. Traditional preclinical models using hERG channel assays and animal studies miss many cardiotoxic compounds while flagging safe drugs as dangerous. Human iPSC-derived cardiomyocytes and cardiac organoids provide species-specific data that better predicts human responses. The CiPA initiative (Comprehensive in vitro Proarrhythmia Assay) developed by FDA and HESI now provides a regulatory-accepted framework for using these human models in safety assessment, potentially transforming how cardiac liability is evaluated during drug development.

Endpoint	What It Measures	Clinical Relevance
Beat Rate	Contraction frequency (bpm)	Bradycardia/tachycardia risk
QT Interval	Repolarization duration	Torsades de pointes arrhythmia
Contractility	Force and velocity of contraction	Cardiac function impairment
Calcium Transients	Intracellular Ca²⁺ dynamics	Excitation-contraction coupling
Arrhythmia Events	Early afterdepolarizations (EADs)	Pro-arrhythmic liability
Structural Markers	Troponin, BNP release	Cardiomyocyte injury

Frequently Asked Questions

What is the CiPA initiative?

The Comprehensive in vitro Proarrhythmia Assay (CiPA) is an FDA/HESI initiative that provides a new paradigm for cardiac safety testing. It combines human iPSC-cardiomyocyte assays, ion channel data, and in silico modeling to predict pro-arrhythmic risk more accurately than traditional hERG-only screening. CiPA is now part of ICH S7B/E14 guidelines.

Why are iPSC-cardiomyocytes better than hERG assays?

hERG assays only measure one potassium channel, while real cardiac toxicity involves multiple ion channels and complex cellular physiology. iPSC-cardiomyocytes express all cardiac ion channels, contract, and show human-specific responses. They detect cardiotoxicity that hERG misses and clear safe drugs that hERG falsely flags as dangerous.

How do cardiac organoids differ from 2D cardiomyocytes?

Cardiac organoids self-organize into 3D structures with chamber-like organization and multiple cell types (cardiomyocytes, fibroblasts, endothelial cells). They model structural cardiotoxicity, developmental effects, and tissue-level responses that 2D monolayers cannot capture. Some organoids even recapitulate early heart development.

What is structural cardiotoxicity?

Structural cardiotoxicity refers to drug-induced damage to heart muscle cells themselves, as opposed to electrical effects. Cancer drugs like doxorubicin and tyrosine kinase inhibitors can cause cardiomyocyte death, fibrosis, and heart failure. Structural toxicity is detected by troponin release, sarcomere disorganization, and mitochondrial dysfunction in cardiac models.

Can cardiac models predict patient-specific responses?

Yes, iPSC-cardiomyocytes derived from specific patients capture their genetic background and drug response phenotypes. Patients with long QT syndrome, hypertrophic cardiomyopathy, or other genetic heart conditions can have their cells used to test drug safety for their specific condition before prescribing.

How is contractility measured in cardiac models?

Contractility is measured using video microscopy tracking of beating motion, impedance-based sensors that detect cell movement, or direct force measurements in engineered heart tissues. Parameters include beat rate, contraction amplitude, velocity of shortening, and relaxation time - all clinically relevant for assessing cardiac function effects.

What drugs have been withdrawn for cardiac toxicity?

Notable withdrawals include cisapride, terfenadine, and rofecoxib (Vioxx) - all of which showed cardiac toxicity in humans that animal models failed to predict. These failures drove development of human-based cardiac models. Modern iPSC-cardiomyocyte assays correctly identify these drugs as cardiotoxic, validating their predictive value.

How do heart-on-chip platforms add value?

Heart-on-chip platforms add mechanical stretching to simulate cardiac workload, perfusion for nutrient delivery and drug exposure, and integrated sensors for real-time monitoring. The mechanical stimulation improves cardiomyocyte maturation and function, making the models more physiologically relevant for drug testing.

Cardiac Safety Testing